drugset / Trial / NCT05898451
Effect of Refnot on Immunity in Cancer Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study was planned to include disseminated patients with various solid tumors (melanoma, soft tissue sarcoma, breast cancer, colon cancer, etc.). The study drug was administered subcutaneously at a dose of 400,000 IU once a day, 3 times a week (every other day), for 4 weeks. In the absence of disease progression - an additional 4 weeks.
Timeline
- Start
- 2009-06-04
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TNF-T | Protein / enzyme biologic | 400000 iu | Subcutaneous |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Dacarbazine | Small molecule | — | — |
| Background | Lomustine | Small molecule | — | — |